Technical Analysis for SLS - SELLAS Life Sciences Group, Inc.

Grade Last Price % Change Price Change
B 10.53 2.83% 0.29
SLS closed up 2.83 percent on Friday, September 17, 2021, on 72 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up
Historical SLS trend table...

Date Alert Name Type % Chg
Upper Bollinger Band Walk Strength 0.00%
Multiple of Ten Bullish Other 0.00%
Above Upper BB Strength 0.00%
Overbought Stochastic Strength 0.00%
Up 3 Days in a Row Strength 0.00%
Up 4 Days in a Row Strength 0.00%
Up 5 Days in a Row Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
Multiple of Ten Bullish Other 2.83%
Above Upper BB Strength 2.83%
Older End-of-Day Signals for SLS ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

SELLAS Life Sciences Group, Inc. Description

SELLAS Life Sciences Group, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications. The company's lead product candidate is galinpepimut-S (GPS), a wilms tumor 1 targeting peptide-based cancer immunotherapeutic agent, which has entered in Phase III clinical trials for the treatment of acute myeloid leukemia; and is in various development phases as a potential treatment for ovarian cancer. It also develops nelipepimut-S (NPS) that is in Phase 2b clinical trials for the treatment of breast cancer; GALE-301 and GALE-302, which is in Phase 1/2a trials in ovarian and endometrial cancers. The company has strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and Advaxis, Inc. on a research program to evaluate, through a proof of principle trial, a clinical candidate, which comprises the combination of proprietary Lm-based antigen delivery technology and GPS. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Clinical Medicine Solid Tumors Oncology Cancer Treatments Breast Cancer Treatment Of Breast Cancer Acute Myeloid Leukemia Ovarian Cancer Immunotherapies Antineoplastic Drugs Hematologic Malignancies Oncolytics Biotech Novel Cancer Treatment Of Acute Myeloid Leukemia Endometrial Cancer Gynaecology Pembrolizumab Gynaecological Cancer Ovarian And Endometrial Cancers

Is SLS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 19.38
52 Week Low 2.11
Average Volume 246,836
200-Day Moving Average 8.78
50-Day Moving Average 9.21
20-Day Moving Average 9.49
10-Day Moving Average 9.73
Average True Range 0.55
ADX 15.69
+DI 24.05
-DI 10.71
Chandelier Exit (Long, 3 ATRs) 8.98
Chandelier Exit (Short, 3 ATRs) 9.80
Upper Bollinger Bands 10.28
Lower Bollinger Band 8.69
Percent B (%b) 1.16
BandWidth 16.77
MACD Line 0.22
MACD Signal Line 0.10
MACD Histogram 0.1234
Fundamentals Value
Market Cap 99.63 Million
Num Shares 9.46 Million
EPS -1.35
Price-to-Earnings (P/E) Ratio -7.79
Price-to-Sales 0.00
Price-to-Book 4.42
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 11.57
Resistance 3 (R3) 11.49 11.06 11.40
Resistance 2 (R2) 11.06 10.79 11.10 11.34
Resistance 1 (R1) 10.79 10.63 10.93 10.88 11.28
Pivot Point 10.37 10.37 10.43 10.41 10.37
Support 1 (S1) 10.10 10.10 10.23 10.18 9.78
Support 2 (S2) 9.67 9.94 9.71 9.72
Support 3 (S3) 9.41 9.67 9.66
Support 4 (S4) 9.49